Bismuth quadruple regimen with tetracycline or doxycycline versus three‐in‐one single capsule as third‐line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp‐EuReg)

Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori

(2019) Olga P. Nyssen et al.   HELICOBACTER

Protocol of the European Registry on the management of Helicobacter pylori infection (Hp‐EuReg)

(2019) Adrian G. McNicholl et al.   HELICOBACTER

Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies

(2018) David Y. Graham et al.   Expert Review of Anti-Infective Therapy

Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI

(2018) David Y. Graham et al.   HELICOBACTER

Reply

(2017) Carlo A. Fallone et al.   GASTROENTEROLOGY

Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study

(2017) Enrique Rodríguez de Santiago et al.   HELICOBACTER

Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies

(2017) Javier P. Gisbert et al.   HELICOBACTER

Doxycycline in Eradication Therapy of Helicobacter pylori - A Systematic Review and Meta-Analysis

(2016) Yaron Niv   DIGESTION

IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori

(2016) Javier P. Gisbert et al.   Gastroenterologia y Hepatologia

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

(2016) Carlo A. Fallone et al.   GASTROENTEROLOGY

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains

(2016) Nelly Muller et al.   Clinics and Research in Hepatology and Gastroenterology

Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection

(2016) Ignasi Puig et al.   Therapeutic Advances in Gastroenterology

How to Effectively Use Bismuth Quadruple Therapy

(2015) David Y. Graham et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection

(2015) Seong tae Lee et al.   Gut and Liver

A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment ofHelicobacter pyloriInfection: A Pilot Study

(2015) Antonio Francesco Ciccaglione et al.   HELICOBACTER

Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication ofHelicobacter pylori

(2014) J. C. Delchier et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Triple Therapy with High-Dose Proton-Pump Inhibitor, Amoxicillin, and Doxycycline Is Useless forHelicobacter pyloriEradication: A Proof-of-Concept Study

(2014) Nuno Almeida et al.   HELICOBACTER

Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection

(2013) J. P. Gisbert et al.   DIGESTIVE DISEASES AND SCIENCES

A review of rescue regimens after clarithromycin-containing triple therapy failure (forHelicobacter pylorieradication)

(2013) Alicia C Marin et al.   EXPERT OPINION ON PHARMACOTHERAPY

Helicobacter pyloriresistance to antibiotics in Europe and its relationship to antibiotic consumption

(2012) Francis Megraud et al.   GUT

Greater Than 95% Success with 14-day Bismuth Quadruple Anti-Helicobacter pyloriTherapy: A Pilot Study in US Hispanics

(2012) Cesar O. Salazar et al.   HELICOBACTER

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

(2011) Peter Malfertheiner et al.   LANCET

A new, single-capsule bismuth-containing quadruple therapy

(2011) Javier P. Gisbert   Nature Reviews Gastroenterology & Hepatology

Bismuth-Containing Quadruple Therapy as Second-Line Treatment forHelicobacter pyloriInfection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate in Korea

(2010) Byoung Hwan Lee et al.   HELICOBACTER

Pylera®for the eradication ofHelicobacter pyloriinfection

(2009) Aamir Saleem et al.   Expert Review of Anti-Infective Therapy

Helicobacter pyloriEradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens

(2009) Tajana Filipec Kanizaj et al.   HELICOBACTER

Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH

(2008) Julia Kirchheiner et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY